한올소개
연구개발
제품정보
ESG
투자정보
뉴스룸
Contact Us
CONTACT US
A Better Tomorrow with HanAll
Innovative Therapeutics to Address Unmet Medical Needs of Patients
Developing Innovations for Healthier,Longer lives for Patients
Committed to Pioneering NextGeneration Technology
HanAll Reports Full-Year 2025 Financial Results and Business..
- Full-year 2025 net revenue reaches 155 billion KRW, driven by double-digit gr..
Statement on HL161 Licensing Agreement Termination Notificat..
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company..
HanAll Biopharma Announces Orphan Drug Designation for Batoc..
- Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for..
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmac..
- HL192 (ATH-399A) was well tolerated with no major safety issues in any of the..
HanAll Biopharma Reports Q3 2024 Financial Results and Prov..
-HanAll records revenue of 36.8 billion KRW in the third quarter, with an opera..
HanAll Biopharma Reports Q2 2024 Financial Results and Provi..
- HanAll reports strong financial performance with second quarter total revenue..
HanAll Biopharma Appoints Christopher W Slavinsky as Chief B..
HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Christophe..
HanAll Biopharma Signs Licensing Agreement with Turn Biotech..
- Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Agin..